The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
Abstract
OBJECTIVES: Endotoxin is a potent stimulus of proinflammatory response and systemic coagulation in patients with severe sepsis. Endotoxin is a component of Gram-negative bacteria that triggers an innate immune response through Toll-like receptor 4 signaling pathways in myeloid cells. We evaluated safety and tolerability of two dose regimens of eritoran tetrasodium (E5564), a synthetic Toll-like receptor 4 antagonist, and explored whether it decreases 28-day mortality rate in subjects with severe sepsis. DESIGN: Prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-dose phase II trial. SETTING: Adult intensive care units in the United States and Canada. PATIENTS: Three hundred adults within 12 hrs of recognition of severe sepsis, with Acute Physiology and Chronic Health Evaluation (APACHE) II-predicted risk of mortality between 20% and 80%. INTERVENTIONS: Intravenous eritoran tetrasodium (total dose of either 45 mg or 105 mg) or placebo administered every 12 hrs for 6 days. MEASUREMENTS AND MAIN RESULTS: Prevalence of adverse events was similar among subjects treated with 45 mg or 105 mg of eritoran tetrasodium or with placebo. For modified intent-to-treat subjects, 28-day all-cause mortality rates were 26.6% (eritoran tetrasodium 105 mg), 32.0% (eritoran tetrasodium 45 mg), and 33.3% in the placebo group. Mortality rate in the eritoran tetrasodium 105-mg group was not significantly different from placebo (p = .335). In prespecified subgroups, subjects at highest risk of mortality by APACHE II score quartile had a trend toward lower mortality rate in the eritoran tetrasodium 105-mg group (33.3% vs. 56.3% placebo group, p = .105). A trend toward a higher mortality rate was observed in subjects in the lowest APACHE II score quartile for the eritoran 105-mg group (12.0% vs. 0.0% placebo group, p = .083). CONCLUSIONS: Eritoran tetrasodium treatment appears well tolerated. The observed trend toward a lower mortality rate at the 105-mg dose, in subjects with severe sepsis and high predicted risk of mortality, should be further investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A network-based analysis of systemic inflammation in humans
Program, I. A. H. R. T. I. L. S. C. R., Calvano, S. E., Xiao, W., Richards, D. R., Felciano, R. M., Baker, H. V., Cho, R. J., Chen, R. O., Brownstein, B. H., Cobb, J. P., et al. (2005) · Nature · doi:10.1038/nature03985 · Cited by 1,429 · cited 1×
“Endotoxin, when administered intravenously to healthy volunteers, stimulates proinflammatory and thrombotic responses observed in severe sepsis patients (1, 2).”
BackgroundOpal, S. M., Scannon, P. J., Vincent, J., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999) · The Journal of Infectious Diseases · doi:10.1086/315093 · Cited by 609
Self-citation
Cited by
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202290 · Cited by 1,309
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.2194 · Cited by 812
Self-citationTLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis
Kuzmich, N., Sivak, K., Chubarev, V., Porozov, Y., Savateeva-Lyubimova, T., & Peri, F. (2017) · Vaccines · doi:10.3390/vaccines5040034 · Cited by 633
Austin, P. J., & Moalem-Taylor, G. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.013 · Cited by 607
Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., & Remick, D. G. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130327 · Cited by 549
Modulating immunity as a therapy for bacterial infections
Hancock, R. E. W., Nijnik, A., & Philpott, D. J. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2745 · Cited by 535
Lucas, K., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8425-7 · Cited by 466
Host innate immune responses to sepsis
Wiersinga, W. J., Leopold, S. J., Cranendonk, D. R., & van der Poll, T. (2014) · Virulence · doi:10.4161/viru.25436 · Cited by 460
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
Iskander, K. N., Osuchowski, M. F., Stearns-Kurosawa, D. J., Kurosawa, S., Stepien, D., Valentine, C., & Remick, D. G. (2013) · Physiological Reviews · doi:10.1152/physrev.00037.2012 · Cited by 453
The TLR4 antagonist Eritoran protects mice from lethal influenza infection
Shirey, K. A., Lai, W., Scott, A. J., Lipsky, M., Mistry, P., Pletneva, L. M., Karp, C. L., McAlees, J., Gioannini, T. L., Weiss, J., et al. (2013) · Nature · doi:10.1038/nature12118 · Cited by 423
The molecular basis of the host response to lipopolysaccharide
Bryant, C. E., Spring, D. R., Gangloff, M., & Gay, N. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2266 · Cited by 391
“; these trials were initially not very promising, owing to poor patient selection, but recent data suggest a trend towards reduced mortalit”
ResultFink, M. P. (2014) · Virulence · doi:10.4161/viru.26083 · Cited by 391
Gao, W., Xiong, Y., Li, Q., & Yang, H. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00508 · Cited by 353
Signaling pathways and intervention therapies in sepsis
Zhang, Y.-Y., & Ning, B.-T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 349
The emerging role of Toll-like receptor 4 in myocardial inflammation
Yang, Y., Lv, J., Jiang, S., Ma, Z., Wang, D., Hu, W., Deng, C., Fan, C., Di, S., Sun, Y., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.140 · Cited by 337
Structural Biology of the Toll-Like Receptor Family
Kang, J. Y., & Lee, J.-O. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052909-141507 · Cited by 331
Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock
Leligdowicz, A., Dodek, P. M., Norena, M., Wong, H., Kumar, A., & Kumar, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1875oc · Cited by 274
Toll-like Receptors in the Vascular System: Sensing the Dangers Within
Goulopoulou, S., McCarthy, C. G., & Webb, R. C. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.010090 · Cited by 263
Savva, A., & Roger, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00387 · Cited by 261
Immune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 259
Salguero, M., Al‑Obaide, M., Singh, R., Siepmann, T., & Vasylyeva, T. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7943 · Cited by 257
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies
Barochia, A., Solomon, S., Cui, X., Natanson, C., & Eichacker, P. Q. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.558190 · Cited by 169
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Nguyen, M., Gautier, T., Masson, D., Bouhemad, B., & Guinot, P.-G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072579 · Cited by 25
“It is also possible to directly target the LPS-TLR-4axis by anti-LPS [75,76] treatment, TLR-blockade [77,78] or anti-cytokine treatment [79,80].”
Background
Metadata
- Authors
- Tidswell, M., Tillis, W., LaRosa, S. P., Lynn, M., Wittek, A. E., Kao, R., Wheeler, J., Gogate, J., & Opal, S. M.
- Venue
- Critical Care Medicine
- Published
- 2010-01
- Volume
- 38
- Issue
- 1
- Pages
- 72-83
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2138167941
- Cited by
- 229
- References
- 2
- FWCI
- 16.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.